Zentalis Pharmaceuticals (ZNTL) Operating Expenses (2022 - 2025)
Historic Operating Expenses for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $33.7 million.
- Zentalis Pharmaceuticals' Operating Expenses fell 3441.05% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.1 million, marking a year-over-year decrease of 2309.52%. This contributed to the annual value of $258.6 million for FY2024, which is 1365.23% down from last year.
- Latest data reveals that Zentalis Pharmaceuticals reported Operating Expenses of $33.7 million as of Q3 2025, which was down 3441.05% from $36.1 million recorded in Q2 2025.
- In the past 5 years, Zentalis Pharmaceuticals' Operating Expenses registered a high of $103.9 million during Q2 2023, and its lowest value of $33.7 million during Q3 2025.
- Moreover, its 4-year median value for Operating Expenses was $62.7 million (2023), whereas its average is $60.1 million.
- As far as peak fluctuations go, Zentalis Pharmaceuticals' Operating Expenses surged by 6374.78% in 2023, and later crashed by 4465.22% in 2025.
- Over the past 4 years, Zentalis Pharmaceuticals' Operating Expenses (Quarter) stood at $51.8 million in 2022, then soared by 31.24% to $67.9 million in 2023, then grew by 12.94% to $76.7 million in 2024, then plummeted by 56.03% to $33.7 million in 2025.
- Its Operating Expenses stands at $33.7 million for Q3 2025, versus $36.1 million for Q2 2025 and $45.6 million for Q1 2025.